Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.57B |
| 2 |
Tesla
TSLA
|
+$1.06B |
| 3 |
Amazon
AMZN
|
+$597M |
| 4 |
Qualcomm
QCOM
|
+$374M |
| 5 |
AbbVie
ABBV
|
+$373M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$1.54B |
| 2 |
Johnson & Johnson
JNJ
|
+$561M |
| 3 |
UnitedHealth
UNH
|
+$353M |
| 4 |
Meta Platforms (Facebook)
META
|
+$345M |
| 5 |
Starbucks
SBUX
|
+$340M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.21% |
| 2 | Technology | 12.9% |
| 3 | Consumer Discretionary | 10.45% |
| 4 | Financials | 8.48% |
| 5 | Industrials | 7.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
901
Barclays
BCS
$94.4B
| $24.5M | 0.02% |
2,577,686
+595,486
| +30% | +$5.14M |
|
902
Xerox
XRX
$412M
| $24.5M | 0.02% |
+663,824
| New | +$23.2M |
|
903
Enterprise Financial Services Corp
EFSC
$2.41B
| $24.4M | 0.02% |
505,700
-19,900
| -4% | -$883K |
|
904
Adtran
ADTN
$665M
| $24.2M | 0.02% |
2,451,428
+134,400
| +6% | +$1.28M |
|
|
ABB
905
DELISTED
ABB Ltd
ABB
| $24.2M | 0.02% |
1,004,500
-1,542,900
| -61% | -$33.1M |
|
906
Zymeworks
ZYME
$1.77B
| $24.2M | 0.02% |
531,595
+156,088
| +42% | +$5.67M |
|
907
Medtronic
MDT
$116B
| $24.1M | 0.02% |
212,800
-1,259,379
| -86% | -$138M |
|
|
UCFC
908
DELISTED
United Community Financial Corp
UCFC
| $24.1M | 0.02% |
2,069,703
+31,599
| +2% | +$353K |
|
|
ZEN
909
DELISTED
ZENDESK INC
ZEN
| $24.1M | 0.02% |
+314,800
| New | +$23.1M |
|
910
Independent Bank Corp
IBCP
$854M
| $24.1M | 0.02% |
1,064,600
+50,700
| +5% | +$1.12M |
|
911
CRISPR Therapeutics
CRSP
$5.22B
| $24M | 0.02% |
394,564
+355,264
| +904% | +$19.4M |
|
912
American International
AIG
$39.8B
| $24M | 0.02% |
+467,060
| New | +$24.7M |
|
913
First Horizon
FHN
$12.3B
| $23.9M | 0.02% |
1,446,127
+914,741
| +172% | +$14.8M |
|
|
BCPC
914
Balchem Corp
BCPC
$5.65B
| $23.8M | 0.02% |
234,408
+2,100
| +0.9% | +$212K |
|
915
Tilly's
TLYS
$121M
| $23.7M | 0.02% |
1,938,721
+118,267
| +6% | +$1.25M |
|
916
Conduent
CNDT
$241M
| $23.7M | 0.02% |
3,826,631
-783,869
| -17% | -$4.9M |
|
917
Cardlytics
CDLX
$24.7M
| $23.7M | 0.02% |
37,714
+27,420
| +266% | +$13.4M |
|
|
ANH
918
DELISTED
Anworth Mortgage Asset Corporation
ANH
| $23.6M | 0.02% |
6,718,490
+156,800
| +2% | +$542K |
|
919
Comtech Telecommunications
CMTL
$52.1M
| $23.6M | 0.02% |
665,150
+160,700
| +32% | +$5.52M |
|
|
CUTR
920
DELISTED
Cutera, Inc.
CUTR
| $23.6M | 0.02% |
659,000
| – | – |
|
921
Box
BOX
$4.48B
| $23.6M | 0.02% |
1,403,812
-726,200
| -34% | -$12.2M |
|
922
EXL Service
EXLS
$5.36B
| $23.5M | 0.02% |
1,691,010
-175,540
| -9% | -$2.4M |
|
923
Cincinnati Financial
CINF
$26.5B
| $23.4M | 0.02% |
222,646
+216,946
| +3,806% | +$23.7M |
|
924
Gilat Satellite Networks
GILT
$895M
| $23.3M | 0.02% |
2,957,417
+8,159
| +0.3% | +$65.3K |
|
|
VLRS
925
Controladora Vuela Compania de Aviacion
VLRS
$906M
| $23.3M | 0.02% |
2,235,748
+586,048
| +36% | +$6.25M |
|
Similar funds
Jim Simons's Q4 2019 Portfolio in Review
As of Q4 2019, Jim Simons held 3,913 positions worth $130B, up 10% from $118B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Jim Simons's Q4 2019 filing shows 518 new, 1,836 increased, 1,085 reduced and 443 closed positions. Its largest new stake was Amazon: 6,745,100 shares worth $623M. The largest sale was Celgene Corp, an estimated $1.54B.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2019 buy was Amazon: 6,745,100 shares worth $623M.
- Jim Simons added most to Bristol-Myers Squibb in Q4 2019, an estimated $1.57B increase.
- Jim Simons's biggest Q4 2019 reduction was Johnson & Johnson, cutting an estimated $561M.
- Jim Simons fully exited Celgene Corp in Q4 2019, selling an estimated $1.54B.
- Jim Simons's ten largest holdings make up 13% of its $130B portfolio in Q4 2019.
- Jim Simons opened 518 new positions and closed 443 in Q4 2019.
- Jim Simons's portfolio value rose 10% quarter-over-quarter to $130B.
Based on Renaissance Technologies's 13F filing for Q4 2019, filed 13 Feb 2020.